August 5, 2008
Listen to Audio (6 min.)
Please note: These files can be quite large. Allow some time for them to download.
Can you tell me your name and where you're from, and a little bit about your poster?
I'm Anna Foss, from London School of Hygiene & Tropical Medicine, in the U.K. My poster is on "HIV/AIDS and Rape, and Modeling Predictions of the Increase in Individual Risk of Contracting HIV from Forced Sex."1 What we did here was a big literature review, looking at the different factors that might be involved -- from violence or forced sex -- in terms of increasing a woman's risk of acquiring HIV. In particular, looking at genital injury. We discovered that there's nothing in the literature that clarifies how genital injury might translate, to the per-sex act probability of HIV transmission.
When we did a comparison using this risk equation, we asked: What if we compare conflict scenario versus a comparison to a more consensual scenario? The conflict scenarios are based around things like forced sex and females selling sex to male members of a peacekeeping force, females being raped by men in a refugee camp; but also considering things like population movement. So you might have people moving from a higher exposed area to a lower exposed area, or the opposite of that.
You can see, actually, that with the risk ratios generated, some of them you can get as high as about four or five times risk because of the conflict, compared to if there had been no conflict. But you can sometimes get a reduction, because you have an influx of lower risk coming in.
So you found a risk ratio, in some cases, as high as 5.3. What's the typical general risk ratio for HIV acquisition for a sex act? How is this different from a typical act of unprotected sex?
The comparison is exactly what we've done here. We're comparing say, an adult female who is raped by three men in a refugee camp, and also has this low-risk male partner who is just her normal partner and she has three consensual sex acts with her low-risk male partner. But the additional risk in the conflict scenario is that she's also raped by three men at the refugee camp.
So what we're saying is that in this conflict scenario, because of the rape, she's five times more likely to contract HIV than if she's only had these consensual sex acts with her usual partner.
I think the key, if I could just sort of say the key kind of conclusions for me, really, is that we're looking at the individual's risk. I think other researchers are looking at population level, perhaps a prevalence, which isn't a very sensitive indicator, really. So here we're looking at an individual level.
The same with STI treatment, where sometimes at a population level, it's hard to see an effect. But individually STI treatment is helping to control HIV transmission. The scenarios, actually, because of the maths, a lot of factors cancel out -- a lot of the uncertainties cancel out -- and all you need to know, actually, is how much more likely is a perpetrator to have HIV or STI than a non-perpetrator, or how many more sex acts versus partners. It's lots of mathematical tradeoffs that cancel out the uncertainties, which is quite helpful really in trying to parameterize the model.
The key thing is really that rape and coercion should be considered in HIV programming, and we're trying to do this kind of quite simple scenario-based work just to highlight that and bring that to the forefront of the agenda a bit more.
It's been nice to see some of the panels, panel discussions and other presentations here, trying to raise this issue more and look more at structural interventions, beyond the biomedical, and looking more at the whole, the broader context, in which, are women able to say no to sex? And what effect does that have on the ABC [Abstinence, Be Faithful, Use Condoms], exactly, than the biomedical interventions?
Thank you very much.
This transcript has been lightly edited for clarity.
No comments have been made.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.